Revenues Revenues

3 Months Ended

Mar. 31, 2020

Revenue from Contract with Customer [Abstract]

Revenues

Revenues

Product Revenues

Revenues by product are summarized as follows:

	For the Three Months Ended March 31,
(In millions)	2020						2019
	United States		Rest of World		Total		United States		Rest of World		Total
Multiple Sclerosis (MS):
Fumarate*	$	777.5	$	323.3	$	1,100.8	$	717.7	$	281.1	$	998.8
Interferon**	292.6		173.4		466.0		327.3		173.6		500.9
TYSABRI	277.7		244.7		522.4		245.0		215.4		460.4
FAMPYRA	—		28.3		28.3		—		22.9		22.9
Subtotal: MS product revenues	1,347.8		769.7		2,117.5		1,290.0		693.0		1,983.0
Spinal Muscular Atrophy:
SPINRAZA	235.4		329.6		565.0		223.3		295.2		518.5
Biosimilars:
BENEPALI	—		133.5		133.5		—		124.0		124.0
IMRALDI	—		61.6		61.6		—		35.7		35.7
FLIXABI	—		23.7		23.7		—		14.7		14.7
Subtotal: Biosimilar product revenues	—		218.8		218.8		—		174.4		174.4
Other:
FUMADERM	—		3.3		3.3		—		4.1		4.1
Total product revenues	$	1,583.2	$	1,321.4	$	2,904.6	$	1,513.3	$	1,166.7	$	2,680.0

*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became available in the U.S. in November 2019.

**Interferon includes AVONEX and PLEGRIDY.

We recognized revenues from two wholesalers accounting for 30.0% and 14.6% of gross product revenues for the three months ended March 31, 2020, and 31.3% and 14.2% for the three months ended March 31, 2019.

An analysis of the change in reserves for discounts and allowances is summarized as follows:

(In millions)	Discounts			Contractual Adjustments			Returns			Total
Balance, as of December 31, 2019	$	131.1		$	1,027.3		$	40.5		$	1,198.9
Current provisions relating to sales in current year	200.7			827.9			4.7			1,033.3
Adjustments relating to prior years	(0.5		)	(15.9		)	(0.5		)	(16.9		)
Payments/credits relating to sales in current year	(73.4		)	(310.3		)	—			(383.7		)
Payments/credits relating to sales in prior years	(112.2		)	(432.8		)	(4.8		)	(549.8		)
Balance, as of March 31, 2020	$	145.7		$	1,096.2		$	39.9		$	1,281.8

The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:

(In millions)	As of March 31, 2020		As of December 31, 2019
Reduction of accounts receivable, net	$	235.4	$	197.8
Component of accrued expenses and other	1,046.4		1,001.1
Total revenue-related reserves	$	1,281.8	$	1,198.9

Revenues from Anti-CD20 Therapeutic Programs

Revenues from anti-CD20 therapeutic programs are summarized below. For the purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.

	For the Three Months Ended March 31,
(In millions)	2020		2019
Biogen’s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA	$	341.3	$	390.8
Other revenues from anti-CD20 therapeutic programs	179.1		126.6
Total revenues from anti-CD20 therapeutic programs	$	520.4	$	517.4

For additional information on our collaboration arrangements with Genentech, please read Note 18, Collaborative and Other Relationships, to our consolidated financial statements included in our 2019 Form 10-K.

Other Revenues

Other revenues are summarized as follows:

	For the Three Months Ended March 31,
(In millions)	2020		2019
Revenues from collaborative and other relationships:
Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis	$	3.7	$	24.8
Profit (loss) earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc.	0.2		(0.4		)
Other royalty and corporate revenues:
Royalty	11.4		3.9
Other corporate	94.0		264.1
Total other revenues	$	109.3	$	292.4

Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic partners, including Bioverativ Inc. (Bioverativ). During the three months ended March 31, 2019, we recognized $206.8 million in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business.

During the third quarter of 2019 we amended our agreement with a contract manufacturing customer. Under the amended agreement, we license certain of our manufacturing-related intellectual property to the customer. We are eligible to receive up to $500.0 million in a series of three payments. The first payment is due upon a regulatory achievement related to the customer’s product manufactured using our manufacturing-related intellectual property, with subsequent payments payable upon the first and second anniversaries of the regulatory achievement. We expect the regulatory achievement to occur in 2020. If we earn this payment, we expect to allocate the consideration between the license for the manufacturing-related intellectual property and the manufacturing product supply services.